Challenges in Biosimilar Pharmacovigilance

Challenges in Biosimilar Pharmacovigilance Photo

This session of the Biosimilars 2016 will investigate the future and FDA activities that have just been reported to incorporate upgraded following and follow-up of post advertising reconnaissance issues, arranged enhancements in AERS, and pilots of new post showcase tranquilize checking techniques and ADR related issues. Biosimilar rules for pharmacovigilance practice and pharmacoepidemiology are the focuses that should be laid accentuation in this session. U.S. normal yearly spending development from 2002 to 2007 was 16% for biologics, contrasted and 3.7% for drugs. In same extent pharmacovigilance for biosimilars has been comparatively more than other pharmaceutical items.

  • Current problems in pharmacovigilance
  • Role of pharma industries in the improvement of pharmacovigilance system
  • Detection and evaluation of drug safety signals
  • Adverse drug reactions with pharmaceutical products
  • Good pharmacovigilance practice and pharmacoepidemiology

Are you interested in

Mail us at

Programs & Speaking Engagement
biosimilars@alliedmeetings.com
Sponsorship
john.wilson@alliedmeetings.com
Group Discounts and Delegates
biosimilars@alliedmeetings.com
More details about sponsorship:sponsors@alliedacademies.com

Authorization Policy

By registering for the conference you grant permission to Allied Academies to photograph, film or record and use your name, likeness, image, voice and comments and to publish, reproduce, exhibit, distribute,broadcast,edit and/or digitize the resulting images and materials in publications, advertising materials,or in any other form worldwide without compensation. Taking of photographs and/or video taping during any session is prohibited. Contact us for any queries
Copyright © 2017-2018 Allied Academies, All Rights Reserved.